摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-benzyl 3-[7-oxo-(4'-N-Boc-6-spiropiperidinyl)-1,8-naphthyridin-3-yl]acrylate | 941604-38-2

中文名称
——
中文别名
——
英文名称
(E)-benzyl 3-[7-oxo-(4'-N-Boc-6-spiropiperidinyl)-1,8-naphthyridin-3-yl]acrylate
英文别名
tert-butyl 2-oxo-6-[(E)-3-oxo-3-phenylmethoxyprop-1-enyl]spiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-1'-carboxylate
(E)-benzyl 3-[7-oxo-(4'-N-Boc-6-spiropiperidinyl)-1,8-naphthyridin-3-yl]acrylate化学式
CAS
941604-38-2
化学式
C27H31N3O5
mdl
——
分子量
477.56
InChiKey
MZSUOICUXVMWAX-MDZDMXLPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    35
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    97.8
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
    申请人:Pauls Henry
    公开号:US20090156578A1
    公开(公告)日:2009-06-18
    In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed.
    本发明的部分涉及具有FabI抑制性质的化合物。这些化合物也可能抑制其他酶,包括那些在结构或功能上类似于FabI的酶,例如Fab K。还提供了包括所述化合物的试剂盒和组合物。还揭示了治疗细菌性疾病患者的方法。
  • [EN] FUSED PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS PYRIDINE FONDUS, EN TANT QU'AGENTS ANTIBACTÉRIENS
    申请人:AURIGENE DISCOVERY TECH LTD
    公开号:WO2014072930A2
    公开(公告)日:2014-05-15
    The present invention relates to fused pyridine derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors, in which P, Q, R1, R2, R3 and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FABI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • WO2007/67416
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多